vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and INVESTORS TITLE CO (ITIC). Click either name above to swap in a different company.
INVESTORS TITLE CO is the larger business by last-quarter revenue ($69.5M vs $44.9M, roughly 1.5× AbCellera Biologics Inc.). On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 14.0%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
ABCL vs ITIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $69.5M |
| Net Profit | $-8.9M | — |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 13.8% |
| Net Margin | -19.9% | — |
| Revenue YoY | 788.4% | -1.6% |
| Net Profit YoY | 73.9% | — |
| EPS (diluted) | $-0.03 | $3.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $69.5M | ||
| Q3 25 | $9.0M | $73.0M | ||
| Q2 25 | $17.1M | $73.6M | ||
| Q1 25 | $4.2M | $56.6M | ||
| Q4 24 | $5.0M | $70.6M | ||
| Q3 24 | $6.5M | $68.8M | ||
| Q2 24 | $7.3M | $65.4M | ||
| Q1 24 | $10.0M | $53.5M |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $12.2M | ||
| Q2 25 | $-34.7M | $12.3M | ||
| Q1 25 | $-45.6M | $3.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $9.3M | ||
| Q2 24 | $-36.9M | $8.9M | ||
| Q1 24 | $-40.6M | $4.5M |
| Q4 25 | -63.7% | 13.8% | ||
| Q3 25 | -851.8% | 20.7% | ||
| Q2 25 | -290.2% | 21.5% | ||
| Q1 25 | -1479.6% | 7.2% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | -1439.4% | 16.8% | ||
| Q2 24 | -1276.2% | 17.2% | ||
| Q1 24 | -551.5% | 10.8% |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | 16.7% | ||
| Q2 25 | -203.3% | 16.7% | ||
| Q1 25 | -1077.2% | 5.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | 13.5% | ||
| Q2 24 | -504.3% | 13.6% | ||
| Q1 24 | -408.0% | 8.5% |
| Q4 25 | $-0.03 | $3.97 | ||
| Q3 25 | $-0.19 | $6.45 | ||
| Q2 25 | $-0.12 | $6.48 | ||
| Q1 25 | $-0.15 | $1.67 | ||
| Q4 24 | — | $4.41 | ||
| Q3 24 | $-0.17 | $4.92 | ||
| Q2 24 | $-0.13 | $4.70 | ||
| Q1 24 | $-0.14 | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $268.3M |
| Total Assets | $1.4B | $363.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $89.6M | ||
| Q3 25 | $83.2M | $110.8M | ||
| Q2 25 | $92.4M | $90.1M | ||
| Q1 25 | $159.3M | $81.7M | ||
| Q4 24 | $156.3M | $83.8M | ||
| Q3 24 | $126.6M | $112.9M | ||
| Q2 24 | $148.3M | $111.2M | ||
| Q1 24 | $123.6M | $135.0M |
| Q4 25 | $966.9M | $268.3M | ||
| Q3 25 | $964.0M | $278.0M | ||
| Q2 25 | $1.0B | $266.2M | ||
| Q1 25 | $1.0B | $254.4M | ||
| Q4 24 | $1.1B | $251.8M | ||
| Q3 24 | $1.1B | $271.3M | ||
| Q2 24 | $1.1B | $261.8M | ||
| Q1 24 | $1.1B | $254.0M |
| Q4 25 | $1.4B | $363.1M | ||
| Q3 25 | $1.4B | $363.3M | ||
| Q2 25 | $1.4B | $345.8M | ||
| Q1 25 | $1.3B | $333.8M | ||
| Q4 24 | $1.4B | $333.6M | ||
| Q3 24 | $1.4B | $352.0M | ||
| Q2 24 | $1.4B | $340.3M | ||
| Q1 24 | $1.5B | $329.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $30.9M |
| Free Cash FlowOCF − Capex | $-44.6M | $25.4M |
| FCF MarginFCF / Revenue | -99.4% | 36.5% |
| Capex IntensityCapex / Revenue | 21.9% | 8.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $30.9M | ||
| Q3 25 | $-52.6M | $17.2M | ||
| Q2 25 | $-32.4M | $8.9M | ||
| Q1 25 | $-11.6M | $-75.0K | ||
| Q4 24 | $-108.6M | $29.8M | ||
| Q3 24 | $-28.9M | $7.8M | ||
| Q2 24 | $-30.0M | $8.4M | ||
| Q1 24 | $-41.7M | $1.4M |
| Q4 25 | $-44.6M | $25.4M | ||
| Q3 25 | $-61.5M | $15.8M | ||
| Q2 25 | $-45.8M | $7.3M | ||
| Q1 25 | $-22.2M | $-1.4M | ||
| Q4 24 | $-187.0M | $22.4M | ||
| Q3 24 | $-47.4M | $6.1M | ||
| Q2 24 | $-50.1M | $6.3M | ||
| Q1 24 | $-65.8M | $-793.0K |
| Q4 25 | -99.4% | 36.5% | ||
| Q3 25 | -687.0% | 21.7% | ||
| Q2 25 | -267.9% | 9.9% | ||
| Q1 25 | -524.0% | -2.5% | ||
| Q4 24 | -3702.8% | 31.7% | ||
| Q3 24 | -728.4% | 8.8% | ||
| Q2 24 | -683.8% | 9.7% | ||
| Q1 24 | -661.5% | -1.5% |
| Q4 25 | 21.9% | 8.0% | ||
| Q3 25 | 99.7% | 1.8% | ||
| Q2 25 | 78.2% | 2.1% | ||
| Q1 25 | 251.1% | 2.4% | ||
| Q4 24 | 1552.7% | 10.5% | ||
| Q3 24 | 284.6% | 2.5% | ||
| Q2 24 | 274.6% | 3.2% | ||
| Q1 24 | 242.5% | 4.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
